Table 1 Patient characteristics
Patient number | Age (years) | Gender | RA duration (years) | Disease-modifying antirheumatic drugs | Steroids (mg/day) | CCP-Ab (U/ml) (t0) | DAS28 | X-ray progression | Response after 3 months | |
|---|---|---|---|---|---|---|---|---|---|---|
Baseline | 3 months | |||||||||
1 | 77 | Male | 21 | None | 5.0 | 644 | 5.45 | 4.69 | No | Nonresponder |
2 | 64 | Male | 27 | Leflunomide | 10.0 | 610 | 5.18 | 4.61 | No | Nonresponder |
3 | 43 | Female | 33 | Methotrexate | 7.5 | 81 | 4.82 | 0.69 | No | Responder |
4 | 65 | Female | 45 | None | 15.0 | 187 | 6.00 | 6.44 | Yes | Nonresponder |
5 | 63 | Female | 8 | None | 15.0 | >1,600 | 5.83 | 8.37 | Yes | Nonresponder |
6 | 51 | Female | 17 | Methotrexate | 20.0 | Negative | 6.16 | 4.40 | Yes | Nonresponder |
7 | 34 | Female | 9 | None | 0.0 | 806 | 5.37 | 5.47 | Yes | Nonresponder |
8 | 44 | Male | 9 | None | 15.0 | Negative | 5.51 | 2.55 | No | Responder |
9 | 39 | Male | 1 | Methotrexate | 5.0 | Negative | 5.12 | 2.09 | No | Responder |
10 | 42 | Female | 29 | Methotrexate | 7.5 | Negative | 6.52 | 1.79 | No | Responder |
11 | 26 | Female | 2 | None | 0.0 | Negative | 4.47 | 1.50 | No | Responder |
12 | 48 | Female | 24 | Leflunomide | 8.0 | 429 | 5.57 | 2.73 | No | Responder |
13 | 47 | Female | 13 | Cyclosporin A | 10.0 | 96 | 7.11 | 5.29 | No | Responder |
14 | 53 | Female | 5 | Leflunomide | 8.0 | 1064 | 3.29 | 2.42 | No | Nonresponder |
15 | 62 | Female | 13 | Methotrexate | 0.0 | Neg. | 5.88 | 4.40 | No | Responder |
16 | 65 | Female | 2 | Sulfasalazine/hydroxychloroquin | 15.0 | >1,600 | 7.68 | 5.90 | No | Responder |
17 | 42 | Female | 14 | None | 5.0 | 61 | 5.6 | 3.36 | No | Responder |
18 | 52 | Female | 8 | Methotrexate | 0.0 | 436 | 5.59 | 2.38 | No | Responder |
19 | 70 | Female | 14 | Leflunomide | 7.5 | 855 | 5.08 | 2.55 | No | Responder |